Method for autohaemotherapy in acupuncture points in integrated treatment of knee arthrosis deformans

FIELD: medicine.

SUBSTANCE: mixture of 0.5% Novocaine or 0.25% Lidocaine 19.0ml and venous autoblood 1.0 ml is administered into the acupuncture points fu-tu and zu-san-li once every day or every second day in total number of blocks 8-16, in an amount of 5 ml into each point at a penetration depth of 1.5-2.0 cm.

EFFECT: reducing pain syndrome and oedema of paraarticular tissues, improving support ability of the lower extremities and knee joint functions by improving microcirculation in the lower extremities.

4 ex

 

The invention relates to medicine and can be used in the treatment of gonarthrosis.

It is known that medical treatments are not always effective and often have side effects.

Currently, widespread autohemotherapy - subcutaneous or intramuscular injection of patient's own blood taken from a vein. Autohemotherapy relates to immunotherapy.

Further development of autohemotherapy is autohemotherapy when autochrome is injected into acupuncture points, thus achieving their long-term stimulation and due to the absorption of biologically active substances from decaying autologous blood recovery of the immune system, normalizing blood, stimulating and invigorating effect.

Therapeutic effects of acupuncture and autologous blood, entered in biologically active points (BAP), primarily due to the influence of the neuroendocrine and the reticuloendothelial system, the functional state which is activated by the formation at the injection site of istochnikov.

Closest to the present invention is a method of treatment of osteoarthritis of the knee irritation (reiterei), combining two methods: autohemotherapy and acupuncture developed by A. A. Guryanova. "Autochrome the patient in the best of the e from drugs, introduced into the BATH, has organ-specific property, which excludes the possibility of individual intolerance. Due to the fact that the blood contains different proteins and cellular structures, the method has diverse effects, in particular hyposensitizing. In response to the introduction of autologous blood in the body produces biogenic stimulators, which prolong the effect obtained from the classical acupuncture" [Guryanov, A. A. experience in the use of autovivification / A. A. Guryanov // Military. the honey. log. 1987. No. 3. - S. 51-52].

The method consists in the following. From the cubital vein of the patient take 4-5 ml of blood and enter one at 1 ml 4-5 biologically active points. After 3-4 days repeat injections, but in other points. Throughout the course of treatment prescribed 4-5 sessions. The blood is introduced into the BATH intramuscularly, subcutaneously, intradermally, and intradermally with novocaine (4 ml blood and 1 ml of 1% solution of novocaine).

The age of patients was 45 to 50 years. In deforming arthrosis of the knee joint effect was realized in point: Yan-Lin-Chuan UV, Yin-Lin-Chuan AR. xing-Jian 2P, Wei-Zhong W. Wai Guan 5, nei-Guan 6MC, zu-Lin-qi WW, Jung-Yai E. Autohemotherapy was used only in the period of exacerbation. Other methods were not applied.

The task of the invention it is the empowerment of autovivification in the complex treatment of gonarthrosis, the search for new specific lower limb points RTI for targeted impact, improvement of microcirculation in the lower extremities.

The problem is solved by the creation of a method of autohemotherapy in point acupuncture in treatment of deforming arthrosis of the knee joint.

The method is as follows.

In the syringe of 20.0 ml of trying to 19,0 ml of anesthetic (procaine 0.5%. or lidocaine 0.25%), and then it produces the fence autologous blood 1,0 ml of the resulting mixture is injected:

the point fu-Tu 5.0 ml,

the point zu-San-Li in 5.0 ml.

Zu-San-Li - point is located at the upper section of the tibia 3 CUN below the edge nadkarni Cup, outwards from the tibial tuberosity to 1 CUN, between the anterior tibial muscle and the long extensor of the toes. The depth of injection of 1.5-2.0, see

Fu-Tu - point lies laterally and anteriorly from the thighs, abdomen straight muscle of the thigh, above the upper edge of the kneecap on the 6th of tuna. The depth of injection of 1.5-2.0, see

CUN is equal to the distance between the skin folds of the middle phalanx of the bent middle (third finger) of the hand and is about 3,0 see

According to the proposed methodology autohemotherapy is done daily or every other day depending on tolerance to achieve a positive clinical effect, the total amount No. 8-16.

Example 1.

Patient K., 42 L.

Was in the clinic with 22.04.13 on 07.05.13 diagnosed with bilateral gonarthrosis II-IIIa Art. with pain on the left. The patient received a comprehensive physical therapy treatment, FT (magneto-laser therapy), blockages in point of RTIs (Fu-Tu, zu-San-Li) 5 ml composition:

S. Novocaini, a 0.5% 19,0 ml

Autochrome to 1.0 ml.

Made 7 blocks with Autocraft. Pain syndrome was arrested.

Drawn to work with 08.05.13,

Example 2.

Patient X, 64 HP, was treated with 22.08.13 on 20.09.13 with a diagnosis II-IIIa Art. with pain. Bilateral Genu varum.

History repeated conservative treatment in other hospitals brought short and little relief. The patient in treatment with NSAIDs and chondroprotection. Every other day, alternating between the right and left lower limb at the point of RTIs (Fu-Tu, zu-San-Li) was administered 5 ml of a mixture of:

S. Novocaini, a 0.5% 19,0 ml

Autochrome to 1.0 ml.

Just made 16 blocks. After treatment shows positive dynamics: improved the support ability of the extremities, increased range of motion in knee joints. Pain syndrome was arrested.

In satisfactory condition discharged home 20.09.13 under the supervision of a surgeon on a residence.

Example 3.

Patient U., 54 l, the Diagnosis of bilateral gonarthrosis II-IIIa Art. with pain. With 15.07.12 g on 28.07.12, the clinic conducted cured the e NPVS (NOVALIS No. 5), PHYSICAL THERAPY, FT. From the first day of conservative treatment the patient at the point of RTIs Fu-Tu, zu-San-Li) was injected at 5 ml composition:

S. Novocaini, a 0.5% 19,0 ml

Autochrome to 1.0 ml.

On the sixth day of treatment, was arrested pain syndrome, was pastos lower third of the leg. Just made 10 blocks. To work with 29.07.12,

Example 4.

Patient F., 65 L. was treated with 19.09.13 on 10.10.13 diagnosed with bilateral gonarthrosis IIIA-IIIB Art. with severe pain. Bilateral Genu varum.

In the complex treatment of patients completed 12 blocks in point of RTIs (Fu-Tu, zu-San-Li) daily but 5 ml of a mixture of:

S. Novocaini, a 0.5% 19,0 ml

Autochrome to 1.0 ml.

Pain syndrome was arrested. Decreased edema paraartikulyarnye tissues, went edema of the lower third of the tibia and the rear brake. Improved the support ability of the lower limbs and features both knee joints.

The advantages of this technique.

1. Nonspecific immunization of the body.

2. Stimulating effect of the proposed points of RTIs, unable to cause unwanted side-effects on other organs and body systems.

3. Negligible risk of complications (if you are allergic to novocaine may use lidocaine and 0.25%).

4. Improvement of microcirculation in the lower extremities.

5. The use of specific lower extremity points and, as a consequence, a more pronounced effect.

The way autohemotherapy blood from a vein in point acupuncture in treatment of deforming arthrosis of the knee joint, wherein the drug mixture consists of anesthetic and autologous blood, the mixture is injected into the point fu-Tu, zu-San-Li times in 1-2 days total number of blockages 8-16, with a syringe of 20.0 ml of trying to 19,0 ml of anesthetic (procaine 0.5% or lidocaine and 0.25 %), then it produces the fence autologous blood (1.0 ml, the mixture is injected in point fu-Tu and to the point zu-San-Li (5 ml), the depth of injection of 1.5-2.0 see



 

Same patents:

FIELD: medicine.

SUBSTANCE: treating acute knee arthritis is ensured by measuring a pre-therapeutic blood lymphocyte percentage in the patient. That requires performing 5 sessions of finger point massage of the points IV.9, XI.34, VII.60, III.36. If the lymphocyte percentage is less than 25%, Myelopidum 6 mg a day is administered additionally every second day, in number of 5 injections.

EFFECT: reducing the clinical manifestations of acute knee arthritis taking into account the immune state.

3 ex

FIELD: medicine.

SUBSTANCE: method involves doing therapeutic exercises and pulsed ultrasonic therapy at a pulse length of 10 ms. That is combined with the magnetic stimulation of the shoulder girdle muscles: m. trapezius m. deltoideus, m. supraspinatus, m. infraspinatus on the involved side. That involves the exposure in accordance with a stable technique with using paired pulses of the length of 22020 mcs at a pulse repetition frequency of 255 pulse/min and a pulse-to-pulse spacing of 80 ms for 3 min per one field. The exposure intensity is 70-90% of the maximum magnetic induction amplitude 1,300 mT. The total length of the procedure is 12 minutes. Then 30 minutes later, mud therapy is conducted by applications on the involved shoulder joint. A mud cake temperature makes 38-40 degrees, and the length of the exposure makes 20 minutes. The mud therapy is followed by ultrasonic therapy. The exposure covers the rotator cuff and attachment points of the tendons - m. supraspinatus, m. infraspinatus, m. teres minor on the involved side. The exposure follows a labile technique at an intensity of 0.2-0.4 W/cm2 for 2 minutes per each field at the total length of the procedure of 8 minutes. The procedures are daily. The therapeutic course is 8-10 procedures.

EFFECT: method enables clinical effectiveness by recovering the motor activity of the involved extremity and prolongs the remission, prevents the progression of the biomechanical and neurodystrophic disorders, and formation of neurological complications.

1 ex, 4 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: present invention refers to compounds having formula III such as below, wherein: Q represents C(Y3) or N; R represents H, -R1, -R1-R2-R3, -R1-R3 or -R2-R3; R1 represents heteroaryl or heterocyclyl each of which is optionally substituted by one or more C1-6alkyls, hydroxyC1-6alkyls, oxogroups or halogenC1-6alkyls; R2 represents -C(=O), -O, -C(R2')2, -C(R2')2C(=O), -C(R2')2C(=O)NR2', C(R2')2 N(R2')C(=O), -C(=NH), -C(R2')2NR2' or -S(=O)2; each R2' independently represents H or C1-6alkyl; R3 represents H or R4; R4 represents C1-6alkyl, C1-6alkoxygroup, aminogroup, C1-6alkylaminogroup, di(C1-6alkyl)aminogroup, heterocyclyl, C1-10alkylheterocycloalkyl, heterocycloalkylC1-10alkyl each of which is optionally substituted by one or more C1-6alkyls, C1-6alkylaminogroups, di(C1-6alkyl)aminogroups, hydroxygroups, hydroxyC1-6alkyls, C1-6alkoxygroups, oxogroups or halogenC1-6alkyls; X represents CH; X' represents CH; and the rest symbols have values as specified in the patent claim. The compounds of formula III inhibit Bruton's tyrosine kinase (Btk). There are also described compositions containing the compounds of formula III, and at least one carrier, thinner or excipient, and a method for producing the compound of formula X in accordance with the following procedure.

EFFECT: compositions are effective for modulating Btk activity and treating diseases related to Btk hyperactivity, and can be used for treating inflammatory and autoimmune diseases related to disturbed B-cell proliferation, such as rheumatoid arthritis.

22 cl, 2 tbl, 260 ex

FIELD: medicine.

SUBSTANCE: what is described is a biomaterial having a multi-dimensional structure and comprising differentiated MSCs tissue and demineralised bone matrix, wherein the above demineralised bone matrix is dispersed in the differentiated MSCs tissue; a method for preparing and using the same is also presented.

EFFECT: biomaterial is processed as needed and has the mechanical properties required for implantation into the natural involved region.

17 cl, 6 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to balneology. A balneological agent for treating and preventing various diseases is prepared by the gradual and sequential mixing at room temperature of yellow clay, natural brine of Bolshoy Tambukan Lake, sage essence, dimethyl sulphoxide in certain relations.

EFFECT: agent possesses the more prominent therapeutic effect.

5 tbl, 2 ex

FIELD: food-processing industry.

SUBSTANCE: treatment is preceded by measuring a blood lymphocyte percentage. If the measured value is more than 35%, that is combined with point massage and administration of acyclovir. The point massage is performed with fingers. The points IV.9, XI.34, VII.60, III.36 are exposed. The 10-day therapeutic course of acyclovir administration is prescribed. Acyclovir is administered in a dose of 400mg 4 times a day.

EFFECT: relieving clinical manifestations of arthritis, reducing time of treatment taking into account the immune state.

3 ex

FIELD: medicine.

SUBSTANCE: according to the method, the affected joints are exposed. The exposure is performed by electrophoresis with 2% pentoxifylline. The pentoxifylline solution is introduced from an anode at current intensity 15 mA. The 15-minute introduction is performed at current density 0.05-0.1 mA/cm2. The therapeutic course is 10 procedures.

EFFECT: method is non-invasive, easy to implement; it reduces the length of treatment.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents pharmaceutical depot, made for introduction by intra-articular injection into joint of subject, suffering from osteoarthritis, which contains microparticles or nanoparticles, composed of N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-[pyridin-2-ylmethoxy)benzamide or its pharmaceutically acceptable salt and biodegradable copolymer lactic acid-glycolic acid.

EFFECT: invention provides controlled release of active agent and long action without toxic side effects.

13 cl, 5 ex, 3 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention represents a drug for treating osteoarthrosis presented as a soft dosage form, containing glucosamine and methyl salicylate as active substances, and additive agents.

EFFECT: enhanced anaesthetic action and lower toxicity of methyl salicylate.

10 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: composite application of therapeutic preparations is combined with a laser therapy. A basic anti-inflammatory preparation is presented by methotrexate administered subcutaneously in a dose of 15mg once a week, and folic acid administered orally in a dose of 5mg a week. Movalis is additionally prescribed in the form of intramuscular injections in a dose of 15mg once a day. The laser therapy is differentiated depending on a degree of the disease, a degree of endothelial dysfunction manifestation, namely a von Willebrand factor (vWF), haemostasis system activity indices, namely activated partial thromboplastin time (APTT), prothrombin time (PTT), thrombin clotting time (TCT), antithrombin III (AT III), protein C. If observing the degree I of the disease, APTT 30.61.5 sec or more, PTT 19.20.9 sec or more, TCT 15.10.7 sec or more, AT III 92.87.6% or more, protein C 0.920.02 or more, vWF 108.99.6% or less, 6-8 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at a light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day. The degrees II and III of the disease, APTT 22.25.5 sec or less, PTT 12.81.7 sec or less, TCT 11.20.9 sec or less, AT III 85.41.1% or less, protein C 0.840.02 and less, vWF 133.52.2% or more, require performing 10 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at the light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day.

EFFECT: method enables reducing the clinical manifestations of the disease, provides higher effectiveness of the drug therapy by involving the pathological processes in the haemostasis system.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to pharmaceutical industry, namely to a preparation for treating an inflammatory condition related to ischemia. A pharmaceutical preparation for treating the internal inflammatory condition related to ischemia containing: a) normal saline containing at least 105 peripheral mononuclear cells (PMC) or their population per one ml, or b) supernatant of normal saline a), wherein normal saline a) is prepared by culturing the PMC or their population in normal saline free from PMC-proliferating or PMC-activating substances; the PMC or their population is cultured in the environment causing the pre- or intra-culture stress. Using the preparation for producing a therapeutic agent for treating the internal inflammatory condition related to ischemia. A method for preparing the pharmaceutical preparation.

EFFECT: pharmaceutical preparation possesses higher clinical effectiveness in the internal inflammatory processes related to ischemia.

13 cl, 20 dwg, 6 ex

FIELD: food industry.

SUBSTANCE: biologically active food additive contains dry blood of antler deer, an antler concentrate and honey at the following components ratio, wt %. antler concentrate - 8-10; dry blood - 2-3; honey - 87-90.

EFFECT: invention allows to produce an additive having the optimal ratio of components and having high adaptogenic and tonic properties.

4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.

EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a biologically active food supplement. The biologically active food supplement possessing the adaptogenic and tonic action and containing antler reindeer's whole blood, antler concentrate according to Technical Specifications (TU) 9860-010-29734071-11, honey, fruit essence, ascorbic acid and Citrosept Grapefruit taken in certain proportions.

EFFECT: formulation enables preparing the biologically active food supplement possessing the enhanced adaptogenic and tonic action.

2 cl, 8 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to a method of pantohematogen production. The method of the pantohematogen production includes sampling blood six times from June to November from culled stags, blood freezing; in the process of production the defrosted blood is homogenised and mixed with sugar syrup, fruit essence and ascorbic acid, the mixture is pasteurised and a preservative "Citrosept grapefruit" is introduced under certain conditions.

EFFECT: method possesses the expressed general toning and stimulating action.

4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a topical pharmaceutical preparation for treating inflammatory skin pathologies, preferentially an ischemia-related skin pathology. The above preparation contains a supernatant of normal saline prepared by culturing for at least 1 hour peripheral blood mononuclear cells (PBMC) or their subpopulation in normal saline free from substances promoting the PBMC proliferation and activating the PBMC in the stress-inducing environment. Also, the invention refers to a method for producing and using the above preparation.

EFFECT: invention promotes relieving the symptoms of the inflammatory skin pathologies and the healing process.

20 cl, 18 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: method for preparing a haematogenous powder from a blood clot involves blood sampling from animals or humans, setting-out and centrifugation of the blood with forming of blood serum and blood clot; the blood serum is poured off, and the blood clot is poured into a vessel and added with ethanol and incubated; the blood clot is then separated, dried and powdered under certain conditions.

EFFECT: method enables preparing the haematogenous powder from the blood clot containing all primary blood components.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and aims at conservative treatment of plantar fasciitis. That is ensured by administering platelet rich autoplasma in an amount of 2.0 ml for each injection into an attachment point of the plantar aponeurosis to the calcaneum (the heel sac), inner and outer side surfaces of a midfoot, as well as to a plantar surface of the midfoot. The autoplasma is prepared 1-2 hours before the procedure, and it contains from 1243 thousand/mcl to 3029 thousand/mcl platelets. The normal autoplasma contains from 162 thousand/mcl to 358 thousand/mcl platelets. The autoplasma is activated with 0.25% CaCl2 in a ratio of 2:1 with added 5% sodium hydrocarbonate in a ratio of 1:20 to the prepared platelet rich plasma.

EFFECT: above method enables providing pain management, recovering the extremity function, ensuring the stable clinical effect, and preventing complications.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used in treating patients with pancreatonecrosis. For this purpose, opening the omental sac and performing the pancreatic gland abdomination along a lower edge of its body and tail are followed by puncturing retroperitoneal fat with introducing components No.1 and No.2 therein. First, component No.1 consisting of dry lyophilized cryoprecipitate 50-70 g dissolved in normal saline 100 ml is slowly administered. Then 10 minutes later, the retroperitoneal fat is additionally punctured, and component No.2 consisting of NIH sterile thrombin dissolved in 5% s-aminocapronic acid 10 ml is introduced. An artificial fibrin barrier is formed in the retroperitoneal fat 5-7 minutes later by mixing and polymerising the two solutions.

EFFECT: method provides the effective treatment of pancreatonecrosis by forming the artificial fibrin barrier on the way of a potential impregnation of the retroperitoneal fat in an enzymatic fluid.

3 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to a composition for treating dermatologic diseases, preferentially skin itching. The composition causes antiallergic action and is used in treating allergic reactions (rash, urticaria), insect bites, ultraviolet erythema and skin burns. The pharmaceutical composition contains azelastine hydrochloride and benzocaine as active substances, and a hydrophobic ingredient, a hydrophilic ingredient, an emulsifying agent and a pH corrective agent as additive agents. As the pH corrective agent, the composition contains preferentially succinic acid. The pharmaceutical composition is presented as a soft dosage form, preferentially in the form of a cream.

EFFECT: composition according to the invention is characterised by high pharmacologic activity, good package extrusion, and storage-stability.

9 cl, 1 tbl, 14 ex

Up!